Cracking The Code: Understanding Analyst Reviews For Intellia Therapeutics
Portfolio Pulse from Benzinga Insights
In the last three months, 4 analysts have published ratings on Intellia Therapeutics (NASDAQ:NTLA), with a mix of somewhat bullish and indifferent sentiments. The average 12-month price target is $48.25, down 8.39% from the prior average. Key analysts have maintained, raised, or lowered their ratings and price targets based on recent developments.
June 04, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have mixed sentiments on Intellia Therapeutics (NASDAQ:NTLA) with an average 12-month price target of $48.25, down 8.39% from the prior average. Key analysts have maintained, raised, or lowered their ratings and price targets based on recent developments.
The mixed analyst ratings and the slight decline in the average price target suggest a neutral short-term impact on NTLA's stock price. While some analysts are somewhat bullish, others are indifferent, leading to a balanced outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100